The HIV protease inhibitor combo Kaletra (lopinavir/ritonavir) appears no more effective than standard supportive care for people with the new coronavirus, according to the results from one of the first clinical trials of the drug.
But the study suggests it might help people who are treated early. "In hospitalized adult patients with severe COVID-19, no benefit was observed with lopinavir/ritonavir treatment beyond standard care," the study authors concluded.